The myeloablative conditioning regimen that commonly is
used in patients with MM is melphalan 200 mg/m2 over one day
or melphalan 100 mg/m2 over two days. Other regimens such as
melphalan plus total body irradiation, busulfan-based regimens,
high-dose etoposide, and holmium 166-labeled phosphonate are
less favored because of increased toxicities with no added benefi
t (Tariman & Estrella, 2005). Premedications usually are given
prior to high-dose melphalan. SCT or reinfusion is performed
24 hours after high-dose melphalan administration and is considered
as day 0 of SCT. The stem cell reinfusion is performed
in the patient’s room or outpatient suite. Figure 4 describes the
stem cell reinfusion procedure